<DOC>
	<DOCNO>NCT01871805</DOCNO>
	<brief_summary>This non-randomized , open-label , multicenter study evaluate safety efficacy CH5424802/RO5424802 patient ALK-rearranged non-small cell lung cancer fail crizotinib treatment . In Phase I , cohorts patient receive escalate dos CH5424802/RO5424802 orally twice daily . In Phase II , patient fail crizotinib treatment receive recommend phase II dose ( 600 mg ) daily two oral dos .</brief_summary>
	<brief_title>A Study CH5424802/RO5424802 Patients With ALK-Rearranged Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm , locally advanced , amenable curative therapy , metastatic nonsmall cell lung cancer ( NSCLC ) ALKrearrangement confirm FDA approve test NSCLC fail crizotinib treatment Measurable disease define RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 Adequate hematologic , hepatic renal function Prior therapy ALK inhibitor crizotinib Brain leptomeningeal metastasis symptomatic and/or require treatment History serious cardiac dysfunction History current active infection hepatitis B , hepatitis C HIV Clinically significant gastrointestinal abnormality would affect absorption drug Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>